WuXi continues its expansion with the opening of another factory in Changzhou; Swiss biotech makes new acquisition – Endpoints News

CDMO WuXi STA has grown rapidly over the past year and its upcoming opening will expand its offering in the peptides sector.

WuXi has open two new large-scale oligonucleotide and peptide manufacturing facilities at its campus in Changzhou, China, according to the company. However, financial and employment details were not disclosed to Terminal news.

The new 30,000 square foot oligonucleotide development and manufacturing facility contains four oligonucleotide production lines and more than 20 small- and medium-scale production lines that are expected to increase the overall manufacturing capacity of a single synthesis from 1.9 mol to 6.0 mol.

For peptides, WuXi has built a new 22,000 square foot peptide factory which includes three new production lines with reactors that can accommodate up to 1,000 L, increasing the overall volume of the solid-phase peptide synthesis reactor by the company to 6,490 L.

Minzhang Chen

“WuXi STA is committed to supporting partners by enhancing the capability and capability of our new CRDMO modality platform to accelerate the development and commercialization of more innovative therapies for the benefit of patients worldwide,” said Minzhang Chen, co. -CEO of WuXi AppTec and WuXi STA.

The new facility is part of WuXi STA’s CRDMO platform to support not only oligonucleotides and peptides, but also novel monomers and linkers, and complex conjugates, from early discovery to development and commercial production.

WuXi recently opened another High Power API (HPAPI) plant at its Changzhou site located in Jiangsu, China. The new plant is designed to meet the growing demand for high power APIs.

Last year, the company also established facilities in Europe and the United States.

Swiss company Biosynth Carbosynth acquires Dutch peptide manufacturer

Swiss manufacturer Biosynth Carbosynth made another acquisition.

Urs Spitz

The company announcement on Monday that it acquired Pepscan, a Dutch supplier of peptide products and services.

Financial terms of the deal were not disclosed, but the two companies will form Biosynth’s new peptide division. The new division will offer peptides to the pharmaceutical and biotechnology industries as well as the diagnostics and cosmetics industries.

“This allows us to continue to simplify our customers’ supply chains in life sciences, pharmaceuticals and diagnostics, so that they deal with one organization for all their needs. Pepscan is known for its scientific knowledge and expertise and has a complementary manufacturing package to those we already have, including GMP capabilities, so this was a perfect fit,” said Biosynth CEO and President, Urs Spitz.

Biosynth was recently thrown into motion when the company acquired Irish company Aalto Bio Reagents, a developer and supplier of biological materials for the in vitro diagnostics (IVD) and vaccine development industry.

KBI Biopharma and Selexis open a new site in Switzerland

As Switzerland continues to see international and local companies building spaces, two more companies are getting in on the action.

KBI Biopharma and Selexis SA have open a 94,000 square foot facility designed to meet the high demand for biopharmaceutical drug development and manufacturing in Europe.

According to KBI, the facility will support an end-to-end integrated process of Selexis’ cellular line development services as well as KBI’s CDMO services.

Marc Womack

“KBI and Selexis have a long history of success together, our collaboration has accelerated over 60 drug development programs in Europe and globally. The integration of Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience, provides our customers with seamless development and manufacturing, profitable and reliable for their products,” said Mark Womack, CEO of KBI.

According to KBI, the facility will house new labs to support Selexis’ cell line manufacturing and KBI’s process development and cGMP manufacturing. The facility will also feature quality control with a suite for testing labs and single-use cGMP manufacturing trains. The expansion will also create more than 300 new jobs in development, operations and quality assurance.

About Margie Peters

Check Also

Actions that will come into action on November 11, 2022

Alkem Laboratories said the US health regulator issued three observations after inspecting its St Louis-based …